View in browser
invest
bGV

Welcome to the world of bioGLOT Ventures

Newsletter - September 16, 2020

 

In this edition

  • bioGLOT Ventures Invites Investors to Invest in ABL Biotec venture
  • bioGLOT Ventures invites Spin-off and Start-up teams that seek Financing to apply for Free Consultation  
  • bioGLOT Ventures introduces DIAMS iQ - IP management software by Dennemeyer IP Group

Let's talk how we may be of your assistance

    Note that Products, Services & Solutions listed below are supported

    by bioGLOT Ventures in Greece and Cyprus

         
    Message from Theo Zacharis

    Hello first name

     

    We are reaching the 2,000 recipients for our Newsletter and we wish to thank all those who share their thoughts, especially on Linked in, and find our model and services interesting and compelling.

    It is our intention to soon move to more customised Newsletters for different groups with similar interests.  

     

    In this edition we primarily deal with start-up financing and more specifically, of the Biomed sector. Health tech venture-backed investments continued strong in 2019, hitting a record according to a report by Silicon Valley Bank (SVB).

     

    We at bioGLOT Ventures are appealing to

    • the Investors world to discuss about financing Biomed (and other) projects
    • the Start-up community to share their venture plans and apply for free Consultation and support
    We also present DIAMS iQ ― IP management software by Dennemeyer IP Group

     

    bioGLOT Ventures is a member of Cambridge Network
         

    bioGLOT Ventures Invites Investors to Invest in ABL Biotec Venture

    ABL

    Anastasis Biotec Ltd (ABL) is a pre-clinical-stage biopharmaceutical company focused on developing innovative oncology therapeutics that target cancers depended on rogue cells multiplying uncontrollably caused by DNA abnormalities (mutations) in important pathways involved in the generation of cancer and cancer stem cells.

     

    Anastasis Biotec is developing a novel and proprietary treatment; tailor made for patients with cancers that express specific ‘cancer driving mutations’. This treatment, by targeting specific and critical mutations, could potentially provide a breakthrough in the treatment of cancer types with significant clinical unmet need.

    ABL moto

     

    ABL Inventor and CEO, Greek-Cypriot Dr Agamemnon Epenetos, PhD, FRCP has been a practising Oncologist and Cancer Researcher over the last 30 years. He was, until recently, a visiting Professor at Imperial College London and has published widely on novel cancer therapies receiving much international recognition. Dr Epenetos has an impressive portfolio of patents and a pipeline of novel drug candidates.

    Anastasis Biotec Ltd is looking for £5 million for the next round.
    Are you an Investor and wish to know more?
         

    bioGLOT Ventures invites Spin-off and Start-up teams that seek Financing to apply for Free Consultation  

    As we have informed you in a previous Newsletter of ours, for every business we undertake to secure financing we will support a new one with free consultation.

     

    In bioGLOT Ventures we welcome the opportunity to discuss how we can assist your Venture and we invite Spin-offs / Start-ups, especially in the Bio-med sector, to submit their Venture Plans for assessment to bioGLOT Ventures 

    money-grow

    How we can assist you 

    Raising money for your start-up can be like navigating through the Amazon by the stars. With our assistance we will help you to

    • Do a financial model that actually makes sense
    • Do a decent pitch deck
    • Build your narrative you tell investors
    • Understand your strategy and ensure you have a clear focus in execution between milestones
    • Comprehend your key metrics to communicate
    • Figure out which investors to pitch and ensure you connect with them the right way
    • And many other…
    Contact us to learn more
         

    bioGLOT Ventures introduces DIAMS iQ - IP management software by Dennemeyer IP Group

    Dennemeyer logo

    DIAMS iQ is Dennemeyer’s state of the art IP management software is ideal for IP professionals who have a portfolio with an increasing number of IP rights that requires constant supervision, control at your fingertips, and a high level of cost transparency.

     

    This web-enabled Intellectual Property asset management system combines the most valuable features of both a client-server solution and a web-based application.

     

    With integrated document and workflow management functionality, DIAMS iQ has a multitude of IP management tools that support all of your electronic record-keeping needs.

     

    Combined with other patent related services such as Patent Annuities or Patent Prosecution, DIAMS iQ covers the entire bandwidth of your IP portfolio.

    Dennemeyer DIAMS IP Mgt
    Wish to know more?
         

    Keep in touch

    Your feedback is very welcome. Have any questions or you wish to receive more personalised news and offers by us? 

    Contact us 

    Schedule a zoom meeting or email us .

    Meeting
    Email Us

    Thank you,
    The bioGLOT Ventures team

    Follow us

    Stay in touch with us

    Facebook
    LinkedIn
    Twitter

    bioGLOT Ventures, St John’s Innovation Centre, Cowley Road, Cambridge, Cambridgeshire CB4 0WS, UK, +44 01223 667354

    Unsubscribe